阿那白滞素治疗痛风急性发作的随机II期研究
主要终点(24-72小时疼痛强度变化)两组无显著差异(-41.2 vs -39.4,P=0.688),阿那白滞素在多数次要终点更优,可作为传统治疗不适用时的有效选择。
要点
- 阿那白滞素在主要终点疼痛缓解上不优于曲安奈德,但疗效相当。
- 阿那白滞素在多数次要终点(患者和医生整体评估)表现更优。
- 传统治疗不适用时,阿那白滞素是痛风急性发作的有效选择。
核心结论
- 阿那白滞素在主要终点(24-72小时疼痛强度变化)不优于曲安奈德,但疼痛缓解疗效相当,且在多数次要终点更优。
- 阿那白滞素是传统治疗不适用时痛风急性发作的有效选择。
研究设计与样本
- 患者随机接受阿那白滞素(100或200 mg/日×5天,n=110)或曲安奈德(40 mg单次注射,n=55)。
主要发现
- 共治疗301次急性发作(阿那白滞素214次,曲安奈德87次)。
- 首次发作从基线至24-72小时疼痛强度平均下降:阿那白滞素总计-41.2,曲安奈德-39.4(P=0.688)。
- 阿那白滞素在多数次要终点优于曲安奈德,未发现意外安全性问题。
- 抗药抗体存在与不良事件或疼痛缓解改变无关。
关键数值与推荐
- 主要终点:患者评估的最受累关节疼痛强度(视觉模拟量表0-100)从基线至24-72小时的变化。
- 阿那白滞素剂量为100或200 mg/日,疗程5天;曲安奈德为40 mg单次注射。
临床怎么用
- 对于NSAIDs和秋水仙碱不适用的痛风急性发作患者,可考虑使用阿那白滞素。
- 阿那白滞素与曲安奈德在疼痛缓解方面疗效相当,且多数次要终点更优。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of anakinra compared to triamcinolone in the treatment of gout flares. METHODS: Patients for whom nonsteroidal antiinflammatory drugs and colchicine were not suitable treatments were enrolled in this multicenter, randomized, double-blind study with follow-up for up to 2 years. The study was designed to assess superiority of anakinra (100 or 200 mg/day for 5 days) over triamcinolone (40 mg in a single injection) for the primary end point of changed patient-assessed pain intensity in the most affected joint (scored on a visual analog scale of 0-100) from baseline to 24-72 hours. Secondary outcome measures included: safety, immunogenicity, and patient- and physician-assessed global response. RESULTS: One hundred sixty-five patients were randomized to receive anakinra (n = 110) or triamcinolone (n = 55). The median age was 55 years (range 25-83), 87% were men, the mean disease duration was 8.7 years, and the mean number of self-reported flares during the prior year was 4.5. A total of 301 flares were treated (214 with anakinra; 87 with triamcinolone). Anakinra in both doses and triamcinolone provided clinically meaningful reduction in patient-assessed pain intensity in the first and subsequent flares. For the first flare, the mean decline in pain intensity from baseline to 24-72 hours for total anakinra and triamcinolone was -41.2 and -39.4, respectively (P = 0.688). Anakinra performed better than triamcinolone for most secondary end points. There were no unexpected safety findings. The presence of antidrug antibodies was not associated with adverse events or altered pain reduction. CONCLUSION: Anakinra was not superior to triamcinolone for the primary end point, but had comparable efficacy in pain reduction and was favored for most secondary end points. Anakinra is an effective option for gout flares when conventional therapy is unsuitable.
引用
- Saag KG, Khanna PP, Keenan RT, et al. A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol. 2021. PMID: 33605029. doi:10.1002/art.41699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。